Clinical Trials Logo

Clinical Trial Summary

Background:

- Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence. Conduct disorders are often treated with antipsychotic medication. Researchers want to study two types of newer antipsychotics (aripiprizole and risperidone) for children and adolescents with conduct disorders. They will look at how these drugs affect brain activity. To do so, they will give brain activity tests using magnetic resonance imaging (MRI). The tests will compare the results from healthy volunteer children and teens to those of others with behavior problems.

Objectives:

- To see how atypical antipsychotics affect brain activity of children and teenagers with conduct disorders.

Eligibility:

- Children and teenagers between 10 and 18 years of age who have a conduct disorder and are taking aripiprizole.

- Children and teenagers between 10 and 18 years of age who have a conduct disorder and are taking risperidone.

- Children and teenagers between 10 and 18 years of age who have a conduct disorder and are not taking an atypical antipsychotic.

- Healthy volunteers between 10 and 18 years of age.

Design:

- Participants will be screened with a physical exam and medical history. Parents/guardians will be asked questions about their child s feelings, experiences, and behavior. Participants will also answer questions about their feelings and moods.

- This study will involve two visits. Each visit will involve MRI scanning.

- At the first visit, participants will have memory and thinking tests. The tests will involve making decisions or playing games. Some of these tests will use MRI scanning to look at brain activity.

- The second visit will be 3 to 5 months after the first visit. The tests from the first visit will be repeated.


Clinical Trial Description

Objective: To determine the impact, as indexed by BOLD response, of the administration of aripiprazole and risperidone during the treatment of Conduct Disorder (CD) on the pathophysiology of CD.

Study Population: Youth with CD receiving aripiprazole at admission to Boys Town Omaha, youth with CD receiving risperidone at admission to Boys Town Omaha, youth with CD not receiving antipsychotics at admission to Boys Town Omaha, typically developing youth.

Design: The study will involve a 4 (Group: CD receiving aripiprazole at admission, CD receiving risperidone at admission, CD not receiving antipsychotics at admission, typically developing youth) x 2 (Time: At admission vs. four months subsequent to admission [when treatment for the antipsychotic groups will have been tapered off]) design. Principle dependent measures will relate to BOLD response indices of the pathophysiology of CD.

Outcome Measures: Principle dependent measures will relate to BOLD response indices of the pathophysiology of CD. In addition, assessments of symptom severity will be collected, as will measurements of cognitive function. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01867398
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase
Start date April 29, 2013
Completion date May 18, 2015

See also
  Status Clinical Trial Phase
Completed NCT03535805 - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances N/A
Recruiting NCT05449002 - Digital Single Session Intervention for Youth Mental Health N/A
Withdrawn NCT02247986 - Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Phase 1/Phase 2
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02485587 - Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents N/A
Completed NCT00819429 - Supplements and Social Skills Intervention Study N/A
Completed NCT00626236 - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Phase 2
Completed NCT01085305 - The Effectiveness of Parent-Child Interaction Therapy (PCIT) N/A
Completed NCT00250354 - A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Phase 3
Completed NCT00000385 - Long-Term Lithium Treatment for Aggressive Conduct Disorder Phase 3
Withdrawn NCT01443949 - Teenagers, Drug Addiction, and Reward and Impulse Control
Completed NCT04091633 - School Health Implementation Network: Eastern Mediterranean N/A
Completed NCT02563145 - Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT00404911 - Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth N/A
Completed NCT00051727 - Prevention of School Dropout for Mexican American Adolescents Phase 2
Completed NCT02998073 - Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder N/A
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Recruiting NCT06373484 - Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents N/A
Recruiting NCT05637320 - Big Feelings: A Study on Children's Emotions in Therapy N/A